Study

EORTC-1608-BTG

Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients with Anaplastic Astrocytoma or Glioblastoma: A Phase Ib Study

Study documentation Back to result

Trial Status

LT-FU ongoing

Dates

Date of activation: 06-Jun-2018
Date Step1 close: 27-Jul-2021
Date Step2 close: 27-Jul-2021

Data management at EORTC

Yes

Design

Phase 1
Not randomized / N.A.

Targeted Sample size

EORTC Groups: 81 - All Groups: 81

Treatment

Radiotherapy, Drug
Temozolomide, TG02

Study Staff

  • Emilie Le Rhun (Study Coordinator), UniversitaetsSpital Zurich - Neurology Clinic, Zurich
  • Tina Verschuere (Project Manager), EORTC Headquarters, Brussels
  • Beatrice Fournier (Clinical Scientist), EORTC Headquarters, Brussels
  • Anne-Sophie Govaerts (Clinical Scientist), EORTC Headquarters, Brussels
  • Thierry Gorlia (Statistician), EORTC Headquarters, Brussels
  • Maarten Spruyt (Data Manager), EORTC Headquarters, Brussels
  • Axelle Nzokirantevye (Imaging DM), EORTC Headquarters, Brussels
  • Sara Meloen (Pharmacovigilance Manager), EORTC Headquarters, Brussels
  • Hafida Lmalem (Imaging Officer), EORTC Headquarters, Brussels
  • Enrico Clementel (QART Manager), EORTC Headquarters, Brussels
  • Coreen Corning (QART Manager), EORTC Headquarters, Brussels
  • Eliza Starczewska (Regulatory Affairs Administrator), EORTC Headquarters, Brussels

Type of cancer

  • Brain

Participating groups

  • EORTC Brain Tumor Group

Recruiting centers

  • CHRU de Lille (LILLE CEDEX, France)
  • CHU Lyon - Hopital neurologique Pierre Wertheimer (BRON CEDEX, France)
  • Erasmus MC (Rotterdam, Netherlands)
  • Gustave Roussy (VILLEJUIF CEDEX, France)
  • Hopital de La Timone (APHM) (MARSEILLE, France)
  • Medical University of Vienna, University Hospital AKH Vienna (Vienna, Austria)
  • UniversitaetsKlinikum Heidelberg - Head Hospital (Heidelberg, Germany)
  • UniversitaetsSpital Zurich (Zurich, Switzerland)
  • Universitaetsklinikum Bonn (Bonn, Germany)
  • Universitaetsklinikum Regensburg (Regensburg, Germany)
  • University Hospital Frankfurt -Senckenberg Institute of Neurooncology (Frankfurt am Main, Germany)

Protocol summary

http://clinicaltrials.gov/study/NCT03224104

NCT number

NCT03224104

EudraCT

2017-001029-42